Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Trypanosoma brucei | methionyl-tRNA synthetase, putative | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | methionine tRNA synthetase | 0.0066 | 1 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.7556 | 0.7546 |
Plasmodium falciparum | methionine--tRNA ligase | 0.0066 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.7556 | 0.7556 |
Echinococcus multilocularis | methionine tRNA synthetase | 0.0066 | 1 | 0.5 |
Trypanosoma cruzi | methionyl-tRNA synthetase, putative | 0.0066 | 1 | 0.5 |
Loa Loa (eye worm) | methionyl-tRNA synthetase | 0.0066 | 1 | 1 |
Giardia lamblia | Methionyl-tRNA synthetase | 0.0066 | 1 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.7556 | 0.7546 |
Mycobacterium leprae | Probable methionyl-tRNA synthase MetS | 0.0066 | 1 | 0.5 |
Plasmodium vivax | methionine--tRNA ligase, putative | 0.0066 | 1 | 0.5 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.7556 | 0.7556 |
Schistosoma mansoni | methionine-tRNA synthetase | 0.0066 | 1 | 1 |
Onchocerca volvulus | 0.0041 | 0 | 0.5 | |
Toxoplasma gondii | methionyl-tRNA synthetase | 0.0066 | 1 | 0.5 |
Mycobacterium ulcerans | methionyl-tRNA synthetase | 0.0066 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.004 | 0.004 |
Trypanosoma brucei | methionyl-tRNA synthetase, putative | 0.0066 | 1 | 0.5 |
Trichomonas vaginalis | methionine-tRNA synthetase, putative | 0.0066 | 1 | 0.5 |
Leishmania major | methionyl-tRNA synthetase, putative | 0.0066 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | methionyl-tRNA synthetase | 0.0066 | 1 | 0.5 |
Mycobacterium tuberculosis | Methionyl-tRNA synthetase MetS (MetRS) (methionine--tRNA ligase) | 0.0066 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | 6.732 uM | PubChem BioAssay. Luminescence-based biochemical high throughput dose response assay for inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS). (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | 15.05 uM | PubChem BioAssay. Counterscreen Fluorescent Polarization-based biochemical high throughput orthogonal dose response assay for inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.